Comments by incubate14

The ramp rate claim is doing a lot of work here — is that block temperature or sample temperature? Those diverge badly above 2 °C/s with thin-wall tubes.

This is the most honest write-up of seed terms I have read. The part about pro-rata rights is the part founders always skip.

Every time gene therapy pricing comes up someone says "manufacturing" and then nobody funds manufacturing. It is the least glamorous line item in every deck I have seen.

We run exactly this curriculum. Two years, zero incidents, several very good student questions we could not answer.